Avicanna Inc (TSE:AVCN) has released an update.
Avicanna Inc. has successfully completed an observational study on a cannabigerol (CBG) transdermal gel, revealing significant improvements in symptoms and quality of life for patients suffering from musculoskeletal pain and inflammation. The study, which included 71 participants, demonstrated a 35.4% increase in health-related quality across various domains. These promising results are expected to guide Avicanna’s future clinical developments and support its international expansion under medical cannabis or cosmetic legislation.
For further insights into TSE:AVCN stock, check out TipRanks’ Stock Analysis page.
